Scott Vermilyea

765 total citations
19 papers, 564 citations indexed

About

Scott Vermilyea is a scholar working on Molecular Biology, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Scott Vermilyea has authored 19 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Neurology and 9 papers in Cellular and Molecular Neuroscience. Recurrent topics in Scott Vermilyea's work include Parkinson's Disease Mechanisms and Treatments (10 papers), Pluripotent Stem Cells Research (9 papers) and CRISPR and Genetic Engineering (5 papers). Scott Vermilyea is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (10 papers), Pluripotent Stem Cells Research (9 papers) and CRISPR and Genetic Engineering (5 papers). Scott Vermilyea collaborates with scholars based in United States, Australia and Singapore. Scott Vermilyea's co-authors include Marina E. Emborg, Baoyang Hu, Yan Liu, Yan Sun, Xiaoqing Zhang, Huisheng Liu, Lixiang Ma, Su-Chun Zhang, Lu Gao and Su‐Chun Zhang and has published in prestigious journals such as Nature Medicine, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Scott Vermilyea

17 papers receiving 560 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Vermilyea United States 11 373 262 133 113 79 19 564
Jin-Chong Xu United States 10 277 0.7× 235 0.9× 144 1.1× 116 1.0× 73 0.9× 11 575
Kent Imaizumi Japan 14 395 1.1× 201 0.8× 84 0.6× 137 1.2× 68 0.9× 23 591
Nayeon Lee South Korea 11 570 1.5× 371 1.4× 103 0.8× 118 1.0× 87 1.1× 20 755
Andrew P. Tosolini United Kingdom 15 396 1.1× 367 1.4× 217 1.6× 98 0.9× 73 0.9× 25 852
Lena Böhnke United States 4 616 1.7× 279 1.1× 106 0.8× 128 1.1× 124 1.6× 6 813
Yoichi Imaizumi Japan 11 401 1.1× 193 0.7× 88 0.7× 53 0.5× 58 0.7× 21 600
Shigeki Omachi Japan 7 373 1.0× 222 0.8× 72 0.5× 160 1.4× 82 1.0× 9 535
Elizabeth Marlow United States 7 499 1.3× 307 1.2× 81 0.6× 152 1.3× 90 1.1× 17 678
B. C. Blanchard United States 9 447 1.2× 343 1.3× 83 0.6× 237 2.1× 93 1.2× 11 683
Michael Glatza Germany 6 433 1.2× 186 0.7× 133 1.0× 186 1.6× 58 0.7× 7 636

Countries citing papers authored by Scott Vermilyea

Since Specialization
Citations

This map shows the geographic impact of Scott Vermilyea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Vermilyea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Vermilyea more than expected).

Fields of papers citing papers by Scott Vermilyea

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Vermilyea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Vermilyea. The network helps show where Scott Vermilyea may publish in the future.

Co-authorship network of co-authors of Scott Vermilyea

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Vermilyea. A scholar is included among the top collaborators of Scott Vermilyea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Vermilyea. Scott Vermilyea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Barnes, Justin, et al.. (2025). Soluble and Insoluble Lysates from the Human A53T Mutant α-Synuclein Transgenic Mouse Model Induces α-Synucleinopathy Independent of Injection Site. International Journal of Molecular Sciences. 26(13). 6254–6254.
3.
Nanclares, Carmen, Scott Vermilyea, Alfonso Araque, et al.. (2023). Dysregulation of astrocytic Ca2+ signaling and gliotransmitter release in mouse models of α-synucleinopathies. Acta Neuropathologica. 145(5). 597–610. 11 indexed citations
4.
Vermilyea, Scott, et al.. (2022). Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy. Translational Neurodegeneration. 11(1). 34–34. 12 indexed citations
5.
Brodsky, Ethan K., Jonathan A. Oler, Scott Vermilyea, et al.. (2022). Real‐time trajectory guide tracking for intraoperative MRI‐guided neurosurgery. Magnetic Resonance in Medicine. 89(2). 710–720. 5 indexed citations
6.
Tao, Yunlong, Scott Vermilyea, Matthew Zammit, et al.. (2021). Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys. Nature Medicine. 27(4). 632–639. 89 indexed citations
7.
Vermilyea, Scott, Jillian H. Kluss, Jenna Kropp Schmidt, et al.. (2020). In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson’s Disease in Common Marmosets. Scientific Reports. 10(1). 3447–3447. 41 indexed citations
8.
Peters, Samuel T., et al.. (2020). Ablating Tau Reduces Hyperexcitability and Moderates Electroencephalographic Slowing in Transgenic Mice Expressing A53T Human α-Synuclein. Frontiers in Neurology. 11. 563–563. 19 indexed citations
9.
Zammit, Matthew, Yunlong Tao, Scott Vermilyea, et al.. (2020). [18F]FEPPA PET imaging for monitoring CD68-positive microglia/macrophage neuroinflammation in nonhuman primates. EJNMMI Research. 10(1). 93–93. 21 indexed citations
10.
Vermilyea, Scott, et al.. (2019). α-Synuclein Expression Is Preserved in Substantia Nigra GABAergic Fibers of Young and Aged Neurotoxin-Treated Rhesus Monkeys. Cell Transplantation. 28(4). 379–387. 5 indexed citations
11.
Vermilyea, Scott & Marina E. Emborg. (2018). In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology. Stem Cells and Development. 27(14). 960–967. 4 indexed citations
12.
Sison, Samantha L., Scott Vermilyea, Marina E. Emborg, & Allison D. Ebert. (2018). Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson’s Disease-Relevant Phenotypes. Current Neurology and Neuroscience Reports. 18(12). 84–84. 36 indexed citations
13.
Zhou, Bo, Steve S. Ho, Louis C. Leung, et al.. (2018). Haplotype-Phased Common Marmoset Embryonic Stem Cells for Genome Editing Using CRISPR/Cas9. SSRN Electronic Journal. 1 indexed citations
14.
Vermilyea, Scott, Michaël Meyer, Kim Smuga-Otto, et al.. (2017). Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Adult Common Marmoset Fibroblasts. Stem Cells and Development. 26(17). 1225–1235. 25 indexed citations
15.
Vermilyea, Scott & Marina E. Emborg. (2017). The role of nonhuman primate models in the development of cell-based therapies for Parkinson’s disease. Journal of Neural Transmission. 125(3). 365–384. 10 indexed citations
16.
Vermilyea, Scott, Jianfeng Lü, Yunlong Tao, et al.. (2016). Real-Time Intraoperative MRI Intracerebral Delivery of Induced Pluripotent Stem Cell-Derived Neurons. Cell Transplantation. 26(4). 613–624. 11 indexed citations
17.
Vermilyea, Scott & Marina E. Emborg. (2015). α-Synuclein and nonhuman primate models of Parkinson's disease. Journal of Neuroscience Methods. 255. 38–51. 29 indexed citations
18.
Emborg, Marina E., et al.. (2014). Systemic administration of 6-OHDA to rhesus monkeys upregulates HLA-DR expression in brain microvasculature. Journal of Inflammation Research. 7. 139–139. 10 indexed citations
19.
Ma, Lixiang, Baoyang Hu, Yan Liu, et al.. (2012). Human Embryonic Stem Cell-Derived GABA Neurons Correct Locomotion Deficits in Quinolinic Acid-Lesioned Mice. Cell stem cell. 10(4). 455–464. 235 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jin-Chong Xu Breakdown of academic impact, for papers by Kent Imaizumi Breakdown of academic impact, for papers by Nayeon Lee Breakdown of academic impact, for papers by Andrew P. Tosolini Breakdown of academic impact, for papers by Lena Böhnke Breakdown of academic impact, for papers by Yoichi Imaizumi Breakdown of academic impact, for papers by Shigeki Omachi Breakdown of academic impact, for papers by Elizabeth Marlow Breakdown of academic impact, for papers by B. C. Blanchard Breakdown of academic impact, for papers by Michael Glatza
Rankless by CCL
2026